By VETTAPHARMA reporter: GSK plc, Pfizer Inc., and Shionogi & Co., Ltd have announced a strategic agreement to restructure the shareholding of ViiV Healthcare Limited, the global specialist HIV company. Under the agreement, Pfizer’s 11.7% economic interest in ViiV Healthcare will be replaced with an investment by Shionogi, boosting Shionogi’s stake to 21.7%, while GSK maintains a majority economic interest of 78.3%.
As part of the transaction, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion, with Pfizer’s existing holding cancelled. In return, Pfizer will receive $1.875 billion, and GSK will receive a special dividend of $250 million, payable in British Pounds.
ViiV Healthcare is dedicated to advancing treatment and care for people living with HIV, as well as those who could benefit from HIV prevention. David Redfern, Chair of ViiV Healthcare, highlighted that the agreement simplifies the company’s shareholder structure and supports ongoing collaboration with Shionogi to advance the company’s pipeline, especially in long-acting injectable HIV treatment and prevention medicines.
John Keller, Ph.D., Director of the Board at Shionogi, emphasized Shionogi’s commitment to infectious disease research and its continued contribution to ViiV’s HIV research portfolio through existing licensing agreements. The agreement further deepens the strategic partnership between Shionogi, GSK, and ViiV Healthcare.
The transaction remains subject to regulatory clearances in relevant markets and is anticipated to be completed during the first quarter of 2026.
Source credit:
GSK plc, Pfizer Inc., & Shionogi & Co., Ltd. (2026, January 20). GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding. ViiV Healthcare. Click here
Disclaimer:
The contents published on this platform are intended solely for informational and educational purposes. Reports, summaries, and discussions related to clinical trials are based on publicly available data, press releases, scientific publications, and regulatory disclosures available at the time of reporting. The information provided does not constitute medical advice, diagnosis, treatment recommendations, or endorsement of any drug, therapy, or clinical outcome. Clinical trial data are subject to change as studies progress, and results discussed may be preliminary, incomplete, or not yet peer-reviewed. Readers are strongly encouraged to refer to the original clinical trial records, regulatory filings, peer-reviewed articles or related sources for complete, accurate, and up-to-date information. Healthcare professionals and patients should consult qualified medical professionals and relevant regulatory authorities before making any healthcare or treatment decisions. Images used on this platform are illustrative in nature and are intended for conceptual and representational purposes only. They may not depict actual products, facilities, individuals, or events. The platform and its contributors disclaim any liability for actions taken based on the information presented.
